Outcome of the Board Meeting- Financial results for the half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
EP Biocomposites Limited announced its unaudited H1 FY26 (April–September 2025) results, approved by the Board on November 3, 2025. Revenue from operations came in at Rs. 407.48 lakhs, down about 7.5% from Rs. 440.49 lakhs in the same period last year. Profit after tax fell sharply to Rs. 9.04 lakhs from Rs. 20.55 lakhs in H1 FY25, a drop of roughly 56%. Basic EPS for the period stood at Rs. 0.54. The balance sheet shows cash and equivalents dropping to Rs. 87.83 lakhs from Rs. 161.67 lakhs, while short-term borrowings nearly tripled to Rs. 154.36 lakhs from Rs. 52.60 lakhs. Operating cash flow was deeply negative at Rs. -130.64 lakhs. The statutory auditor, S.P. Bhandare & Associates, issued an unqualified limited review report with no qualifications or emphasis matters.
Weak half-year print with both revenue and profits contracting, combined with negative operating cash flow and rising short-term debt, signals near-term stress on the stock. Shareholders should watch for working capital improvement and any reversal in the cash burn in upcoming quarters.